[{"orgOrder":0,"company":"He Eye Hospital","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Diquafosol","moa":"Pyrimidinergic receptor P2Y6 | Pyrimidinergic receptor P2Y4 | Purinergic receptor P2Y1 | Purinergic receptor P2Y2","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"He Eye Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"He Eye Hospital \/ Santen Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"He Eye Hospital \/ Santen Pharmaceutical"}]

Find Clinical Drug Pipeline Developments & Deals for Diquafosol

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          He Eye Hospital

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          He Eye Hospital

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Diquafosol Tetrasodium is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Diabetic Retinopathy.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 14, 2022

                          Lead Product(s) : Diquafosol

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Undisclosed

                          Sponsor : Santen Pharmaceutical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank